4.6 Article

ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy

Journal

GENES
Volume 13, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/genes13050783

Keywords

bioinformatics; neoantigen; proteogenomic; tumor immunotherapy

Funding

  1. National Natural Science Foundation of China [31870829]
  2. Shanghai Municipal Health Commission Collaborative Innovation Cluster Project [2019CXJQ02]

Ask authors/readers for more resources

ProGeo-neo is a proteogenomics-based neoantigen prediction pipeline that identifies MHC-I binding peptides based on SNV mutations. To improve accuracy, we present ProGeo-neo v2.0 with new features including prediction of MHC-II restricted neoantigens and identification of additional candidate neoantigens. We also propose more efficient screening methods to narrow down the range of candidate peptides, providing a more meaningful reference for subsequent experimental validation.
A proteogenomics-based neoantigen prediction pipeline, namely ProGeo-neo, was previously developed by our team to predict neoantigens, allowing the identification of class-I major histocompatibility complex (MHC) binding peptides based on single-nucleotide variation (SNV) mutations. To improve it, we here present an updated pipeline, i.e., ProGeo-neo v2.0, in which a one-stop software solution was proposed to identify neoantigens based on the paired tumor-normal whole genome sequencing (WGS)/whole exome sequencing (WES) data in FASTQ format. Preferably, in ProGeo-neo v2.0, several new features are provided. In addition to the identification of MHC-I neoantigens, the new version supports the prediction of MHC class II-restricted neoantigens, i.e., peptides up to 30-mer in length. Moreover, the source of neoantigens has been expanded, allowing more candidate neoantigens to be identified, such as in-frame insertion-deletion (indels) mutations, frameshift mutations, and gene fusion analysis. In addition, we propose two more efficient screening approaches, including an in-group authentic neoantigen peptides database and two more stringent thresholds. The range of candidate peptides was effectively narrowed down to those that are more likely to elicit an immune response, providing a more meaningful reference for subsequent experimental validation. Compared to ProGeo-neo, the ProGeo-neo v2.0 performed well based on the same dataset, including updated functionality and improved accuracy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available